UCD researchers are among the co-authors of a report which has unlocked the cascade of molecular events that lead to Alzheimer’s disease. The findings published in Nature Medicine (22 June 2008) suggest a potential new target for the development of drug therapies to fight the irreversible and degenerative disease.
Alzheimer’s disease affects more than 40,000 people in Ireland and some 29.8 million people worldwide. The baseline cost of dementia in Ireland was estimated at €400m in 2006 and the total worldwide societal cost was estimated at somewhere in the region of US$315.4 billion in 2005.
The team of Irish and international researchers have identified that the accumulation of a particular protein (called amyloid ß-protein - Aß) in the brain initiates Alzheimer’s disease and directly alters the structure and function of brain cells. The findings place a significant emphasis on the development of new therapeutic strategies targeted at the reduction of the formation of Aß.
“Alzheimer’s disease is a major personal and societal tragedy,” says Professor Ciaran Regan from the UCD School of Biomolecular and Biomedical Science, one of the co-authors of the report. “The disease progression is torturously long and debilitating, extorting a huge emotional and economic cost.”
“The onset of the disease is insidious with the earliest symptoms often manifested as subtle and intermittent deficits of episodic memory,” explains Professor Dominic Walsh, associate Professor of Pharmacology at the UCD Conway Institute, another co-author of the report.
“Our findings support the growing theory that Alzheimer’s disease memory deficits may result from loss of dendritic spines and that this process is mediated by amyloid β–protein (Aβ) oligomers, not monomer or plaque Aβ as previously considered,” Professor Walsh added.
The research is supported by the Wellcome Trust, Science Foundation Ireland and the US National Institutes of Health.
